In practice for more than 16 years, Dr. Chari specializes in plasma cell disorders, including multiple myeloma, amyloid light-chain (AL) amyloidosis, POEMS syndrome, plasmacytoma, and monoclonal gammopathies of uncertain significance (MGUS). He performs a variety of procedures, including bone marrow biopsy and stem cell transplant. Dr. Chari has published extensively on these topics and has been invited to speak regionally, nationally, and internationally at major medical congresses such as the annual meetings of the American Society of Hematology and American Society of Clinical Oncology. In recognition of his efforts, Dr. Chari was named Healthcare Provider of the Year by the Leukemia & Lymphoma Society. Dr. Chari’s research interests include the development of novel chemotherapy regimens, including phase 1 and 2 studies.

He is principal investigator (PI) of several investigator-initiated trials and serves as the national and international PI of several industry-sponsored studies. As the Director of Clinical Research in the Multiple Myeloma Program, he oversees a program renowned nationally for both high-volume patient accruals and rigorous quality assurance. The program has played a pivotal role in the approval of each of the five most recent medicines to be approved by the US Food and Drug Administration for the treatment of multiple myeloma. Dr. Chari received his medical degree from the David Geffen School of Medicine at University of California – Los Angeles. He completed his residency in internal medicine at Columbia University Medical Center and a fellowship in hematology and oncology at the University of California – San Francisco. He received his undergraduate degree from Stanford University.

Dr. Morie Gertz currently holds the title of Professor of Medicine and his primary appointment is as a consultant in the Division of Hematology, Department of Internal Medicine at the Mayo Clinic, Rochester, MN, USA. Dr. Gertz has major research interests in amyloidosis and Multiple Myeloma (MM). In particular, Dr. Gertz studies relapse rates in patients with MM and amyloidosis when treated with novel versus traditional therapies. His areas of focus include primary amyloidosis, stem cell transplantation, amyloidosis and Waldenström’s macroglobulinemia.

Dr. Gertz completed a BA in Arts and Sciences at Northwestern University, before completing his medical studies at the Loyola University & Stritch School of Medicine in Chicago, USA. He then undertook two internships at Saint Joseph’s Hospital and at the Rush Presbyterian-St. Luke’s Medical Center, in Chicago, before taking up a residency in Internal Medicine at Rush Presbyterian-St. Luke’s Medical Center. After this he took up a fellowship at Department of Hematology and Oncology Mayo Graduate School of Medicine, Mayo Clinic College of Medicine, where he has remained for the duration of his career.

Dr. Gertz holds a number of professional affiliations. He is a member of the Committee on Training for the American Society of Hematology, a member of the Hematology Board Exam Committee, American Board of Internal Medicine and was Treasurer of the International Myeloma Society (IMS) from 2011–2014. In recognition of his work, he received the Waldenström Award for medical and scientific achievements in Waldenström’s macroglobulinemia in 2014.